Alteplase
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | ACTIVASE | — | 1995-04-03 – 2005-01-04 | fda.gov ↗ |
| Approved | US (FDA) | ACTIVASE | — | 1987-11-13 | fda.gov ↗ |
Trials 120 · started per year
Also used as a comparator or background therapy in 92 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06760195 Background | Jan → Jun 2025 overdue | ischemic stroke | Capital Medical University | Not yet recruiting | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT06663631 Background | Nov 2024 → Jan 2025 overdue | ischemic stroke | Capital Medical University | Recruiting | No outcome recorded |
| Phase 1 | NCT05258565 Comparator | Mar → Jun 2022 | ischemic stroke | Assiut University | Completed | No outcome recorded |
| Phase 1 | NCT02492477 Background | Jan → Jul 2016 | cancer | Krankenhaus Barmherzige Schwestern Linz | Terminated | No outcome recorded |
| Phase 1 | NCT00283088 Comparator | Oct 2003 → Oct 2008 | ischemic stroke | University of California, San Diego | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01878136 Comparator | Mar 2015 → Sep 2016 | brain aneurysm, hydrocephalus, intracranial vasospasm, subarachnoid hemorrhage | Rush University Medical Center | Withdrawn | No outcome recorded |
| Phase 219 trials | ||||||
| Phase 2 | NCT05281549 Comparator | May 2021 → Jan 2022 | ischemic stroke | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04110275 Comparator | Oct 2019 → May 2021 | pulmonary embolism | Angde Biotech Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04256473 Comparator | Aug 2019 → Mar 2022 | ischemic stroke | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04071613 Comparator | Jun 2019 → Nov 2021 | ischemic stroke | Melbourne Health | Completed | No outcome recorded |
| Phase 2 | NCT03108833 Comparator | Jun 2017 → Dec 2019 | pulmonary embolism | Tasly Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02338466 Comparator | Jul 2016 → Jul 2018 | cerebral arterial disease | University Hospital Center of Martinique | Withdrawn | No outcome recorded |
| Phase 2 | NCT02257294 Comparator | Mar 2016 → Jul 2018 | myocardial infarction | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| Phase 2 | NCT02388061 Comparator | Mar 2015 → Oct 2017 | ischemic stroke | Neuroscience Trials Australia | Completed | No outcome recorded |
| Phase 2 | NCT02347358 Comparator | Feb 2015 → Jan 2017 | ischemic stroke | The Second Artillery General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01869478 Comparator | Jan 2013 → Sep 2015 | ischemic stroke | Mayo Clinic | Terminated | No outcome recorded |
| Phase 2 | NCT01492725 Comparator | Jun 2012 → Dec 2014 | ischemic stroke | Neuroscience Trials Australia | Terminated | No outcome recorded |
| Phase 2 | NCT01472926 Comparator | Dec 2011 → Dec 2013 | ischemic stroke | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| Phase 2 | NCT01464788 Background | Oct 2011 → Jun 2015 | ischemic stroke | Andrew D. Barreto, MD | Terminated | No outcome recorded |
| Phase 2 | NCT01222117 Comparator | Dec 2010 → Dec 2015 | peripheral arterial occlusive disease 1 | Grifols Therapeutics LLC | Completed | No outcome recorded |
| Phase 2 | NCT01133223 Comparator | May 2010 → Sep 2015 | stroke disorder | Hospital de Clinicas de Porto Alegre | Withdrawn | No outcome recorded |
| Phase 2 | NCT01098890 Comparator | Oct 2009 → Oct 2011 | acquired aneurysmal subarachnoid hemorrhage, intracerebral hemorrhage | University of Calgary | Unknown | No outcome recorded |
| Phase 2 | NCT00252239 Comparator | Nov 2005 → Mar 2009 | ischemic stroke | University of Virginia | Terminated | No outcome recorded |
| Phase 2 | NCT00224770 Comparator | Aug 2005 → Aug 2012 | intracerebral hemorrhage | Daniel Hanley | Completed | No outcome recorded |
| Phase 2 | NCT00044057 Background | Dec 2000 → Jan 2003 | ischemic stroke | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT05728333 Comparator | Nov 2023 → Feb 2026 overdue | ischemic stroke | Xinqiao Hospital of Chongqing | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05105633 Comparator | Nov 2021 → May 2028 expected | basilar artery occlusion | University of Melbourne | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03357133 Comparator | Dec 2017 → Jun 2020 | ischemic stroke | Capital Medical University | Terminated | No outcome recorded |
| Phase 2/3 | NCT02180204 Comparator | Jan 2015 → Jun 2020 | ischemic stroke | Reza Behrouz, DO | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT01123161 Comparator | Jun 2010 → Jan 2015 | ischemic stroke | University of California, San Diego | Terminated | No outcome recorded |
| Phase 2/3 | NCT00417768 Comparator | Jul 2005 → Jul 2012 | abscess | University Health Network, Toronto | Terminated | No outcome recorded |
| Phase 328 trials | ||||||
| Phase 3 | NCT07687056 Comparator | Jun 2026 → Dec 2030 expected | ischemic stroke | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06658197 Comparator | Dec 2025 → Dec 2026 expected | intracranial thrombosis, ischemic stroke | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 3 | NCT06878066 Comparator | Mar 2025 → Dec 2028 expected | intracerebral hemorrhage, ischemic stroke | Guri Hagberg | Recruiting | No outcome recorded |
| Phase 3 | NCT06196320 Comparator | Jan 2024 → Sep 2025 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05965193 Background | Aug 2023 → Aug 2025 | ischemic stroke | Ji Xunming,MD,PhD | Unknown | No outcome recorded |
| Phase 3 | NCT05827042 Comparator | May 2023 → Jun 2026 overdue | basilar artery occlusion, stroke disorder | The First Affiliated Hospital of University of Science and Technology of China | Recruiting | No outcome recorded |
| Phase 3 | NCT05700591 Comparator | Jan 2023 → Mar 2024 | ischemic stroke | Tasly Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05745259 Comparator | Oct 2022 → Nov 2023 | ischemic stroke | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04965038 Comparator | Oct 2022 → Mar 2026 | central retinal artery occlusion | University Hospital Tuebingen | Terminated | No outcome recorded |
| Phase 3 | NCT05295173 Comparator | Mar 2022 → Jun 2023 | ischemic stroke | Angde Biotech Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05091320 Comparator | Dec 2021 → Nov 2022 | ischemic stroke | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT04915729 Comparator | Jun 2021 → Oct 2023 | stroke disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT04797013 Comparator | Jun 2021 → May 2022 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04454788 Comparator | Aug 2020 → Jul 2024 | ischemic stroke | University of Melbourne | Terminated | No outcome recorded |
| Phase 3 | NCT03594175 Comparator | Feb 2020 → Jun 2023 | thrombotic disease, vascular occlusion disorder | Chiesi Farmaceutici S.p.A. | Terminated | No outcome recorded |
| Phase 3 | NCT03889249 Comparator | Dec 2019 → Apr 2022 | intracranial thrombosis, ischemic stroke | University of Calgary | Completed | No outcome recorded |
| Phase 3 | NCT03854500 Comparator | Oct 2019 → Sep 2021 | ischemic stroke | Haukeland University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT04088292 Comparator | Jun 2019 → Jun 2024 overdue | pulmonary embolism | Rigshospitalet, Denmark | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03541668 Comparator | May 2018 → Apr 2020 | ischemic stroke | Tasly Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03151993 Comparator | Mar 2017 → Mar 2019 | ischemic stroke | Supergene, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02814409 Comparator | Dec 2016 → Aug 2023 | ischemic stroke | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| Phase 3 | NCT01862458 Comparator | Jan 2016 | empyema | Children's Mercy Hospital Kansas City | Withdrawn | No outcome recorded |
| Phase 3 | NCT07146360 Comparator | May 2014 → Nov 2017 | myocardial infarction | AO GENERIUM | Completed | No outcome recorded |
| Phase 3 | NCT01098981 Comparator | May 2013 → Apr 2015 | ischemic stroke | Cerevast Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01949948 Comparator | Sep 2012 → Dec 2016 | ischemic stroke | Lars Thomassen | Completed | No outcome recorded |
| Phase 3 | NCT00975962 Comparator | Jul 2009 → Mar 2011 | stroke disorder | Aarhus University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00640367 Comparator | Feb 2008 → Feb 2009 | stroke disorder | Niguarda Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02182011 Comparator | May 2000 → Jun 2001 | myocardial infarction | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 415 trials | ||||||
| Phase 4 | NCT07111559 Comparator | Aug 2025 → Mar 2028 expected | brain small vessel disease 4, ischemic stroke | Nippon Medical School | Recruiting | No outcome recorded |
| Phase 4 | NCT05910125 Comparator | Jul 2023 → Jul 2027 expected | ischemic stroke | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06653946 Comparator | Jul 2022 → Jul 2024 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 4 | NCT06058884 Comparator | Jan 2022 → Jun 2023 | ischemic stroke | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 4 | NCT06337175 Comparator | Jun 2021 → Oct 2023 | ischemic stroke | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 4 | NCT05155540 Comparator | Jul 2019 → Jul 2020 | cerebral atherosclerosis, ischemic stroke, venous thromboembolism | Alexandria University | Completed | No outcome recorded |
| Phase 4 | NCT03661411 Comparator | Oct 2018 → Jul 2022 | ischemic stroke | General Hospital of Shenyang Military Region | Completed | No outcome recorded |
| Phase 4 | NCT03394950 Comparator | May 2018 → May 2021 | ischemic stroke | Huisheng Chen | Completed | No outcome recorded |
| Phase 4 | NCT03468933 Comparator | Nov 2017 → Dec 2019 | empyema, pleuropneumonia | Tulane University | Completed | No outcome recorded |
| Phase 4 | NCT02835534 Comparator | May 2016 → Oct 2019 | ST-elevation myocardial infarction | CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02016547 Comparator | Sep 2013 → Feb 2015 | middle cerebral artery infarction | SOS Attaque Cérébrale | Terminated | No outcome recorded |
| Phase 4 | NCT01429350 Comparator | May 2012 → Oct 2016 | ischemic stroke | Penumbra Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02132689 Comparator | Mar 2011 → May 2015 | pulmonary embolism | University Hospital Ostrava | Completed | No outcome recorded |
| Phase 4 | NCT01956955 Comparator | Jan 2011 → Dec 2013 | — | Ataturk University | Unknown | No outcome recorded |
| Phase 4 | NCT01246453 Comparator | Dec 2003 → Dec 2010 | pleural empyema | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase not applicable18 trials | ||||||
| — | NCT06833827 Comparator | Feb 2025 → Jan 2028 expected | pulmonary embolism | Leiden University Medical Center | Recruiting | No outcome recorded |
| — | NCT07360717 Comparator | Nov 2024 → Dec 2025 | — | U. N. Mehta Institute of Cardiology and Research Center | Completed | No outcome recorded |
| — | NCT06241677 Comparator | Apr 2024 → Dec 2028 expected | ischemic stroke | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| — | NCT05903417 Comparator | Jul 2023 → Oct 2025 | respiratory tract infectious disorder | National University of Malaysia | Completed | No outcome recorded |
| — | NCT07374978 Comparator | Jul 2023 → May 2025 | pulmonary embolism | Ain Shams University | Completed | No outcome recorded |
| — | NCT05631847 Comparator | Apr 2023 → Aug 2025 | basilar artery occlusion, ischemic stroke, thrombotic disease | Sichuan Academy of Medical Sciences | Completed | No outcome recorded |
| — | NCT03392792 Comparator | Dec 2018 | — | Assiut University | Unknown | No outcome recorded |
| — | NCT03583931 Comparator | Jul 2018 → Feb 2020 | blood coagulation disease, pleural empyema, pleuropneumonia | Denver Health and Hospital Authority | Completed | No outcome recorded |
| — | NCT03469206 Comparator | Feb 2018 → Oct 2019 | cerebral artery occlusion, ischemic stroke, thrombotic disease | Changhai Hospital | Completed | No outcome recorded |
| — | NCT03192332 Comparator | Nov 2017 → May 2021 | ischemic stroke | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| — | NCT02216565 Background | Dec 2014 → Aug 2015 | ischemic stroke | Fondation Ophtalmologique Adolphe de Rothschild | Terminated | No outcome recorded |
| — | NCT02326428 Background | Mar 2014 → Jan 2018 | ischemic stroke | Karolinska Institutet | Completed | No outcome recorded |
| — | NCT01745692 Background | Dec 2012 → Apr 2015 | ischemic stroke | NHS Greater Glasgow and Clyde | Terminated | No outcome recorded |
| — | NCT01657461 Comparator | Dec 2012 → Jan 2015 | ischemic stroke | Medtronic Neurovascular Clinical Affairs | Completed | No outcome recorded |
| — | NCT01062698 Comparator | Jun 2010 → Dec 2015 | ischemic stroke | Central Hospital, Nancy, France | Terminated | No outcome recorded |
| — | NCT01197573 Comparator | Apr 2010 → Oct 2015 | — | The Cleveland Clinic | Completed | No outcome recorded |
| — | NCT00468104 Comparator | Apr 2004 → Oct 2008 | pleural disorder | Midwest Pulmonary and Critical Care | Completed | No outcome recorded |
| — | NCT01451320 Comparator | Jan 1993 → Dec 2009 | — | Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital | Completed | No outcome recorded |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 224 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alteplase | “We randomly assigned patients with ischemic stroke who were receiving 0.9 mg of alteplase per kilogram of body weight less than 4.5 hours after the onset of ischemic stroke...” PMID 25671797 ↗ Feb 2015137“Patients were randomized within 3 h of onset to receive either intravenous alteplase, in accordance with the current European labeling, or up to 0.9 mg/kg intra-arterial...” PMID 21990564 ↗ Oct 2009 “We included patients with acute ischaemic stroke (National Institutes of Health Stroke Scale score ≥10) who received intravenous thrombolysis (alteplase bolus) within 3 h of...” PMID 30878103 ↗ Apr 2019 “After each catheter placement, subsequent bolus of 1mg of Alteplase (Actilyse, Boehringer Ingelheim)/catheter is administered, followed by continuous infusion at 1...” NCT05493163 ↗ “Standard reperfusion treatment for high-risk PE patients is thrombolytic therapy, typically consisting of Alteplase, Urokinase, or Tenecteplase, with the idea of accelerated...” NCT06833827 ↗ “In the combined treatment group, intravenous alteplase (0·9 mg/kg bodyweight, maximum dose 90 mg per patient) was administered as early as possible after randomisation for 60...” PMID 35810756 ↗ Jul 2022 “Targeted, intracoronary delivery of low-dose recombinant tissue plasminogen activator (alteplase) might be an effective strategy for improving microvascular obstruction without...” PMID 41194755 ↗ Oct 2025 “Standard endovascular techniques to mechanically remove clot material, such as mechanical thrombectomy and/or balloon angioplasty and/or local application of alteplase or...” NCT06583889 ↗ “Recombinant human tissue-type plasminogen activator(rt-PA,chemical name:Alteplase,brand name: Actilyse)50mg/stick,provided by Boehringer Ingelheim Pharma Gesellschaft mit...” NCT04110275 ↗ “Patients randomized to the IPFT study arm will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg BID x 3 days delivered through a chest tube or small bore catheter...” NCT03873766 ↗ “Rt-PA (alteplase) is injected intravenously in the 2 arms of the study for a duration of 60 minutes in the arm with a "classical dose" and 90 minutes in the arm with a "low...” NCT00132509 ↗ “We investigated the safety and efficacy of alteplase, a recombinant tissue plasminogen activator, in combination with minimally invasive surgery (MIS) in patients with...” PMID 27751554 ↗ Oct 2016 “Participants randomised to the IA thrombolysis group will receive IA thrombolysis (tenecteplase or alteplase) at the time of completion of the mechanical thrombectomy part of...” NCT06352632 ↗ “Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose...” NCT06841965 ↗ “alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.” NCT03469206 ↗ “Recombinant tissue-plasminogen activator treatment. Low-dose (0.6mg/kg) alteplase will be given because this dosage is the only dosage approved in Japan.” NCT07111559 ↗ “either standard-of-care alteplase (0·9 mg/kg [maximum 90 mg], administered intravenously with 10% as a bolus over 1 min and 90% as an infusion over 1 h)” PMID 35525251 ↗ May 2022 “intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)” NCT06749834 ↗ “Agent options: alteplase (rt-PA) at 0.225 mg/kg (maximum 22.5 mg) or tenecteplase (TNK) at 0.0625 mg/kg (maximum 6.25 mg), infused over 15-30 minutes.” NCT07668323 ↗ “Intravenous (IV) recombinant tissue plasminogen activator (IV alteplase) is currently the only proven effective medication for the treatment of AIS” NCT05258565 ↗ “Patients will receive intravenous alteplase (0.9mg/kg, maximum 90mg) or tenecteplase (0.25mg/kg, maximum 25mg) before endovascular thrombectomy.” NCT05827042 ↗ “both drugs (Alteplase (ALP) and Tenecteplase (TNK)) are approved drugs for the indication AIS with similar efficacy and safety profile.” NCT06878066 ↗ “Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)” NCT05634382 ↗ “In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours.” NCT04453371 ↗ “Intra-pleural deoxyribonuclease 5mg and intra-pleural Alteplase 10mg, every 12 hours over 72 hours (total of 6 treatments)” NCT02135588 ↗ “medical management of patient according guide lines, either alteplase if presented in it's time window, or anti-platelet” NCT05091320 ↗ “Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses.” NCT01204333 ↗ “Administered a "safe dose" of Alteplase. All patients are treated with low molecular weight heparin” NCT02604238 ↗ “treatment with intravenous alteplase (0.9 mg per kilogram of body weight) or placebo” PMID 18815396 ↗ Sep 2008 “Selectively catheter thrombolysis with alteplase in each main pulmonary” NCT04926428 ↗ “Drug: Alteplase (tPA) Dose: 0.9 mg/kg Route: Intravenous (IV) infusion” NCT05626972 ↗ “Reteplase versus Alteplase for Acute Ischemic Stroke.” PMID 42089199 ↗ May 2026 “standard dose intravenous alteplase (0.9 mg/kg” NCT06841978 ↗ “PCDT will be AngioJet along with alteplase.” NCT04411316 ↗ “1 mg of alteplase is injected as a bolus” NCT06487052 ↗ “YM872 (zonampanel), t-PA (alteplase)” NCT00044057 ↗ “All patients receive IV alteplase” NCT01745692 ↗ “rt-PA--Activase (Alteplase)” NCT00790335 ↗ |
| Known as | Actilyse | “After each catheter placement, subsequent bolus of 1mg of Alteplase (Actilyse, Boehringer Ingelheim)/catheter is administered, followed by continuous infusion at 1...” NCT05493163 ↗9“Alteplase is a recombinant tissue plasminogen activator used for thrombolytic treatment in several indications and is currently approved in Europe under the brand name Actilyse®.” PMID 37248330 ↗ May 2023 “Intravenous infusion in a retinal vein with rtPA (Actilyse 0.25mg/ml).” NCT03417401 ↗ “Intravenous thrombolysis by alteplase (Actilyse) (optional)” NCT02326428 ↗ “Alteplase (rt-PA)/Actilyse” NCT01062698 ↗ |
| Known as | Actilyse Cathflo | “Actilyse Cathflo was added as an additional permitted investigational medicinal product as this is already used in practice in the UK and is molecularly identical to Actilyse 10 mg.” PMID 40229856 ↗ Apr 2025 |
| Known as | Activase | “administration of recombinant tissue plasminogen activator or Activase (Alteplase, rt-PA), which promotes the proteolytic action of plasmin from plasminogen at the site of a clot.” NCT00624000 ↗ |
| Known as | Actylise | “All the patients will be given a 15 minutes IA infusion of alteplase (Actylise®) at a drug concentration of 1.0 mg/ml.” NCT03876119 ↗1“All the patients will be given a 15 minutes IA infusion of alteplase (Actylise®) at a drug concentration of 1.0 mg/ml.” NCT05797792 ↗ |
| Known as | ALP | “both drugs (Alteplase (ALP) and Tenecteplase (TNK)) are approved drugs for the indication AIS with similar efficacy and safety profile.” NCT06878066 ↗ |
| Known as | Alteplase for Injection | “Active Comparator: Alteplase Drug: Alteplase for Injection Dose:50mg;20mg” NCT04028518 ↗ |
| Known as | Alteplase injection (rt-PA) | “Alteplase injection (rt-PA)” NCT04797013 ↗ |
| Known as | Cathflo | “Catheter locking solutions such as recombinant tissue plasminogen activator (rt-PA), Alteplase (Cathflo®) are used to treat and prevent clotting of the catheter during HD...” NCT02474810 ↗1“Cathflo (Alteplase)” NCT01576679 ↗ |
| Known as | Cathflo Activase | “Cathflo Activase (Alteplase)” NCT00307580 ↗ |
| Known as | recombinant human tissue plasminogen activator | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01429350 ↗ |
| Known as | recombinant t-PA | “activase (recombinant tissue plasminogen activator, rt-PA, or recombinant t-PA)” NCT00250991 ↗ |
| Known as | recombinant tissue plasminogen activator | “administration of recombinant tissue plasminogen activator or Activase (Alteplase, rt-PA), which promotes the proteolytic action of plasmin from plasminogen at the site of a clot.” NCT00624000 ↗17“once weekly recombinant tissue plasminogen activator (rtPA) lock therapy more effective than routine care using heparin flushes” NCT02355743 ↗ “activase (recombinant tissue plasminogen activator, rt-PA, or recombinant t-PA)” NCT00250991 ↗ “low-dose recombinant tissue plasminogen activator (rtPA, or alteplase)” NCT00082355 ↗ “intravenous recombinant tissue plasminogen activator (rt-PA)” NCT01869478 ↗ |
| Known as | recombinant tissue plasminogen activator, Alteplase | “recombinant tissue plasminogen activator, Alteplase” NCT01429350 ↗ |
| Known as | recombinant tissue-type plasminogen activator | “Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)” NCT05634382 ↗2“intravenous recombinant tissue-type plasminogen activator (rt-PA) versus intravenous streptokinase” NCT00000505 ↗ “IV r-tPA (recombinant tissue-type plasminogen activator)” PMID 28596447 ↗ Jun 2017 |
| Known as | rt-PA | “An Open Label, Multicenter, Single-arm Trial to Assess Safety and Efficacy of Alteplase (Rt-PA) in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is...” NCT02930837 ↗42“The purpose of this study is to examine the effects of delivering intra-arterial recombinant tissue plasminogen activator (rt-PA) and ultrasound to the site of the blood clot...” NCT00243906 ↗ “Recombinant human tissue-type plasminogen activator(rt-PA,chemical name:Alteplase,brand name: Actilyse)50mg/stick,provided by Boehringer Ingelheim Pharma Gesellschaft mit...” NCT04110275 ↗ “Rt-PA (alteplase) is injected intravenously in the 2 arms of the study for a duration of 60 minutes in the arm with a "classical dose" and 90 minutes in the arm with a "low...” NCT00132509 ↗ “Previous studies on high-dose, short-term thrombolysis with alteplase (rtPA) showed a reduced risk of hemodynamic deterioration but no change in mortality and increased...” PMID 39732696 ↗ Dec 2024 “administration of recombinant tissue plasminogen activator or Activase (Alteplase, rt-PA), which promotes the proteolytic action of plasmin from plasminogen at the site of a clot.” NCT00624000 ↗ “Agent options: alteplase (rt-PA) at 0.225 mg/kg (maximum 22.5 mg) or tenecteplase (TNK) at 0.0625 mg/kg (maximum 6.25 mg), infused over 15-30 minutes.” NCT07668323 ↗ “All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion” NCT06760195 ↗ “Patients received a nebulised version of a type of drug called tissue plasminogen activator (rt-PA) that was inhaled using a nebuliser.” NCT04356833 ↗ “Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)” NCT05634382 ↗ “Intravenous (IV) Alteplase (rt-PA) is the gold standard for brain infarction within 4 h 30 of symptoms onset.” NCT02016547 ↗ “intravenous recombinant tissue-type plasminogen activator (rt-PA) versus intravenous streptokinase” NCT00000505 ↗ “rhPro-UK vs. alteplase (recombinant tissue plasminogen activator [rt-PA]) in patients with aPE.” PMID 41916317 ↗ Mar 2026 “To collect additional confirmatory data on alteplase(rt-PA) in the European setting” NCT00153036 ↗ “activase (recombinant tissue plasminogen activator, rt-PA, or recombinant t-PA)” NCT00250991 ↗ “rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour” NCT01464788 ↗ “low-dose recombinant tissue plasminogen activator (rtPA, or alteplase)” NCT00082355 ↗ “Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)” NCT01657461 ↗ “Intravenous infusion in a retinal vein with rtPA (Actilyse 0.25mg/ml).” NCT03417401 ↗ “intravenous (IV) recombinant human tissue plasminogen activator (rtPA)” NCT01429350 ↗ “IV r-tPA (recombinant tissue-type plasminogen activator)” PMID 28596447 ↗ Jun 2017 “Recombinant Tissue Plasminogen Activator (rt-PA)” NCT00029315 ↗ “recombinant tissue plasminogen activator (rtPA)” PMID 31069128 ↗ Apr 2019 “Intravenous throbolysis with 0.9mg/kg rtPA.” NCT03506009 ↗ “Alteplase (rt-PA)/Actilyse” NCT01062698 ↗ “Alteplase (Rt-PA)” NCT02182011 ↗ |
| Known as | Standard-dose rtPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01422616 ↗ |
| Known as | tissue Plasminogen Activator | “Targeted, intracoronary delivery of low-dose recombinant tissue plasminogen activator (alteplase) might be an effective strategy for improving microvascular obstruction without...” PMID 41194755 ↗ Oct 202533“Complex pleural space infections often require treatment with multiple doses of intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease, with treatment failure...” PMID 38710463 ↗ May 2024 “instillation of intrapleural tissue Plasminogen Activator (TPA) and human recombinant Deoxyribonuclease (DNase) for the management of empyema or complicated parapneumonic...” NCT03468933 ↗ “After chest tube insertion, participants in the treatment group will receive intrapleurally administered tissue plasminogen activator (tPA) 4 mg followed by dornase alfa 5 mg.” PMID 28646887 ↗ Jun 2017 “BACKGROUND: Whether intravenous tissue plasminogen activator (alteplase) is effective beyond 3 h after onset of acute ischaemic stroke is unclear.” PMID 18296121 ↗ Feb 2008 “tissue plasminogen activator (tPA) 10mg will be administered once a day as part of intrapleural enzyme therapy (IET) for 3 consecutive days.” NCT07095361 ↗ “Patients received a nebulised version of a type of drug called tissue plasminogen activator (rt-PA) that was inhaled using a nebuliser.” NCT04356833 ↗ “tissue plasminogen activator (tPA)-a naturally occurring protein that opens blocked arteries by dissolving blood clots” NCT01123161 ↗ “Tissue plasminogen activator (tPA) and DNase are given through the chest tube to help with draining the fluid.” NCT03167281 ↗ “Fibrinolysis With tPA (Tissue Plasminogen Activator) Versus tPA and DNAse in Children With Empyema” NCT01862458 ↗ “recombinant tissue plasminogen activator (rtPA)” PMID 31069128 ↗ Apr 2019 |
| Known as | tissue plasminogen activator (tPA) | “tissue plasminogen activator (tPA)” NCT01222117 ↗ |
| Known as | tissue-type plasminogen activator | “A follow-up trial using the widely available tissue-type plasminogen activator (t-PA) alteplase is now needed to assess optimal dosing and safety in this critically ill patient...” PMID 32838109 ↗ Aug 2020 |
| Known as | tPA | “instillation of intrapleural tissue Plasminogen Activator (TPA) and human recombinant Deoxyribonuclease (DNase) for the management of empyema or complicated parapneumonic...” NCT03468933 ↗23“A follow-up trial using the widely available tissue-type plasminogen activator (t-PA) alteplase is now needed to assess optimal dosing and safety in this critically ill patient...” PMID 32838109 ↗ Aug 2020 “10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily with initial administration occurring at chest tube placement.” NCT03167281 ↗ “After chest tube insertion, participants in the treatment group will receive intrapleurally administered tissue plasminogen activator (tPA) 4 mg followed by dornase alfa 5 mg.” PMID 28646887 ↗ Jun 2017 “Tissue Plasminogen Activator (tPA) is infused through the ClearRRAflow catheter into the ventricular system to promote clearance of intraventricular hemorrhage.” NCT07643493 ↗ “Purpose: to evaluate the effect of intravitreal injection of tissue plasminogen activator(tPA) in treatment of refractory diabetic macular edema(DME).” NCT01141881 ↗ “tissue plasminogen activator (tPA) 10mg will be administered once a day as part of intrapleural enzyme therapy (IET) for 3 consecutive days.” NCT07095361 ↗ “The TIMI trial of tissue plasminogen activator (TPA), which is more clot-specific than streptokinase, has substantiated the effectiveness.” NCT00000468 ↗ “The aim of this study was to determine the lowest optimal tissue plasminogen activator (tPA) dose and delivery duration using” PMID 30025734 ↗ Jul 2018 “DNAse and tPA (tissue plasminogen activator) together i.e. 5mg DNAse and 10mg tPA twice a day for up to six doses” NCT03583931 ↗ “Patients receive tissue plasminogen activator (tPA) IV over 6 hours and oral captopril twice daily on days 1-5.” NCT00086723 ↗ “intrapleural 10 mg alteplase (t-PA) with 5 mg of pulmozyme (DNase) twice daily for 72 h were used.” PMID 35581627 ↗ May 2022 “tPA-a naturally occurring protein that opens blocked arteries by dissolving blood clots” NCT01123161 ↗ “commercially available recombinant tPA (Genentech as Activase®) for IV administration” NCT01591096 ↗ “5-hour infusion of 90 mg t-PA (Tissue plasminogen activator) after 10 mg bolus” NCT01451320 ↗ “Drug: Alteplase (tPA) Dose: 0.9 mg/kg Route: Intravenous (IV) infusion” NCT05626972 ↗ “t-PA (Alteplase) 5mg and DNase (Pulmozyme)5mg” NCT05903417 ↗ “Tissue Plasminogen Activator (tPA)” NCT01478698 ↗ “Group1: IV t-PA and normothermia” NCT01123161 ↗ “Alteplase t-PA” NCT00238537 ↗ |
| Action | Activate | “promotes the proteolytic action of plasmin from plasminogen at the site of a clot” NCT00624000 ↗ |
| Modality | Protein / enzyme biologic | “recombinant tissue-type plasminogen activator (rt-PA)” NCT00000505 ↗ |
| Route | Intravenous | “intravenous rt-PA” NCT00000505 ↗ |